The case: a woman in her 50s on a transdermal estradiol patch, oral micronized progesterone and vaginal estrogen, feeling well, whose coronary calcium score came back at 92. Her cardiologist started rosuvastatin 5 mg; she was already on losartan. The presenting physician kept the patch, added low-dose aspirin and ordered a stress test, but wanted the group's view.
Several physicians answered that transdermal estradiol at that dose does not raise clot risk; only oral estrogen does in the data they cited. A cardiologist reframed the case: a CAC of 92 at that age places her in roughly the 97th percentile, which means accelerated atherosclerosis, so consider CTA or CIMT and look for prothrombotic variants. Others suggested coronary CTA with plaque analysis (Cleerly or HeartFlow), an advanced lipid panel with Lp(a) and ApoB, and a PCSK9 inhibitor. One added a sequencing point: if there is significant inflamed plaque, address it before starting HRT.
Then a member shared a family case: a 49-year-old relative had a lacunar stroke a month or two after starting a 0.05 mg estradiol patch, and a PFO was found. A neurologist explained why that combination is unlikely to be causal: PFO-related strokes are typically cortical, from paradoxical embolism, while lacunar strokes come from small-vessel disease driven by hypertension, diabetes, lipids and smoking. A former structural interventionist added that about 25% of people have a PFO and that closure only helps when the PFO is the true cause, which is why tools like the RoPE score exist.
Others raised recent viral illness as a possible contributor and defended transdermal HRT firmly, citing a relative risk for clots of about 0.9. The member who shared the case closed with a point the room accepted: she has supported HRT for two decades, and nothing in medicine is absolute. The thread showed the network at its best, with clinical rigor and personal experience on the table at the same time.
Key takeaways
- Transdermal estradiol at standard doses has not shown increased clot risk in the data members cited.
- A high CAC for age means accelerated atherosclerosis; characterize the plaque before or alongside HRT decisions.
- Lacunar strokes point to small-vessel disease, not PFO embolism.
- PFO closure helps only when the PFO is the cause; use structured scoring to decide.
From Buzz in the chat, the longevitydocs™ Sunday newsletter, March 8, 2026. Member discussion, not clinical guidance.
Originally published in The Longevity Medicine Intelligence newsletter.
